The 15 references in paper D. Romodanovsky P., T. Eremenkova V., M. Dranitsyna A., D. Goryachev V., R. Niyazov R., E. Gavrishina V., V. Merkulov A., Д. Ромодановский П., Т. Еременкова В., М. Драницына А., Д. Горячев В., Р. Ниязов Р., Е. Гавришина В., В. Меркулов А. (2018) “Высоковариабельные лекарственные препараты - особенности исследования биоэквивалентности // Highly variable medicines - specific aspects of bioequivalence studies” / spz:neicon:vedomostincesmp:y:2015:i:4:p:5-10

1
Shah VP, Yacobi A, Barr WH, Benet LZ, Breimer D, et al. Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res. 1996; (13): 1590–4.
(check this in PDF content)
2
Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, Lee CH, et al. Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Generic Drug Products by the US Food and Drug Administration. The AAPS J. 2012; 14(4): 915–24.
(check this in PDF content)
3
Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, et al. Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications. The AAPS J. 2008; (10): 148–56.
(check this in PDF content)
4
Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 2005; (43): 485–498.
(check this in PDF content)
5
Zhou D. and Qiu Y. Understanding Biopharmaceutics Properties for Pharmaceutical Product Development and Manufacturing I – Oral Absorption and the Biopharmaceutics Classification System. J Validation Tech. 2009; 15(4): 62–72.
(check this in PDF content)
6
On Amendments to the Federal Law «On Circulation of Medicines». The Federal Law of 22.12.2014 No 429-FZ (in Russian).
(check this in PDF content)
7
On Amendments to the Federal Law «On Circulation of Medicines» and the Federal Law «On Amendments to the Federal Law “On Circulation of Medicines”». The Federal Law of 13.07.2015 No 241-FZ (in Russian).
(check this in PDF content)
8
Conducting of qualitative studies of bioequivalence of medicines. Guidelines, approved by Ministry of Health and Social Development of the Russian Federation. Farmakokinetika i farmakodinamika 2005; 1(2): 14 (in Russian).
(check this in PDF content)
9
Zherdev VP, Kolyvanov GB, Litvin AA, Sariev AK. Harmonization of bioequivalence study of medicines: problems and possible solutions. Eksperimentalnaya i klinicheskaya farmakologiya 2003; 66(2): 60–64 (in Russian).
(check this in PDF content)
10
Investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2010/01/WC500070039.pdf.
(check this in PDF content)
11
Draft Guidance on Progesterone. United States Food and Drug Administration. Available from: http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM209294.pdf.
(check this in PDF content)
12
Tothfalusi L, Endrenyi L, Arieta AG. Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet. 2009; (48): 725–43.
(check this in PDF content)
13
Rules of bioequivalence study of drugs of the Eurasian Economic Union (version 2, 20.02.2015). Available from: http://www.eurasiancommission.org/ru/ act/texnreg/deptexreg/konsultComitet/Documents (in Russian).
(check this in PDF content)
14
Hyslop T, Hsuan F, and Holder DJ. A small sample confidence interval approach to assess individual bioequivalence. Stat. Med. 2000; (19): 2885–97.
(check this in PDF content)
15
Tothfalusi L, Endrenyi L, Midha KK, Rawson MJ, Hubbard JW. Evaluation of the Bioequivalence of Highly-Variable Drugs and Drug Products. Pharmaceutical Research 2001; (18): 728–33. R E F E R E N C E S Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Me-
(check this in PDF content)